The slight EPS miss is secondary to the positive pipeline catalysts. Focus on the upcoming enozertinib data at ESMO October 2026 and the rinzimetostat program update in 2H 2026. The Bayer collaboration strengthens the Phase 3 trial setup without diluting ORIC's rights. Monitor cash burn rate relative to the runway into 2H 2028 and any further ATM activity.
Drugs in focus
ORIC drug pipeline →rinzimetostat
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 data is positive (expected 2H 2026), regulatory filing could follow in 2027, with potential FDA approval in 2028 at the earliest.
- Next catalyst
- None dated
What to watchWatch for rinzimetostat Phase 3 data readout expected in 2H 2026 (Himalayas-1 trial in mCRPC). Positive data would be a major catalyst for ORIC stock given rinzimetostat is the company's lead pipeline asset. The Bayer darolutamide collaboration strengthens the trial design without cost to ORIC.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $13.47entry
- T+1 · 3mo ago −4.01%α −3.81% · $12.93
- T+5 · 3mo ago +1.93%α +2.03% · $13.73
- T+20 · 3mo ago −4.31%α −3.07% · $12.89
- T+60 · 20d ago −33.18%α −32.97% · $9.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ORIC reported Q2 2026 net loss of $(0.38) per share, missing consensus of $(0.36) by $0.02. The operational highlight is the initiation of Himalayas-1, a global Phase 3 trial for rinzimetostat in metastatic castration-resistant prostate cancer, and a clinical collaboration with Bayer for darolutamide supply. Cash runway extends into 2H 2028, with key data catalysts expected in 2H 2026.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $(0.38)/share vs consensus $(0.36), a -5.6% miss
- Initiated global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC
- Entered clinical trial collaboration with Bayer to receive darolutamide at no cost for Himalayas-1
- Cash and investments $387.6M, expected runway into 2H 2028
- R&D expenses $36.3M, up 19% YoY due to rinzimetostat advancement
- Raised $59.9M via ATM in Q1 2026 from healthcare specialist funds
- Enozertinib 1L EGFR atypical monotherapy data expected at ESMO October 2026
Financial Impact
Net loss of $41.5M for Q2 2026, versus $36.4M in Q2 2025; EPS miss of $0.02 relative to consensus
Risk Factors
- Clinical trial risk for rinzimetostat Phase 3 (Himalayas-1) given competitive prostate cancer landscape
- Dilution risk from potential further ATM drawdowns
- Cash burn increasing as R&D expands with Phase 3 costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337877 |
Track record
12 reports on ORIC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
- Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
- Aug 3, 202615w ago Press Release Neutral 5/10 Viewing Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers